Dr. Jun Wang is currently an Assistant Professor of Pathology at NYU Grossman School of Medicine. Dr. Wang possesses around two decades of expertise in immunotherapy, focusing on the discovery of novel immune receptor-ligand pathways and their utilization for treating cancer, autoimmune, and other human diseases. In addition to his early experience with liver toxicities of anti-4-1BB immunotherapy, he has characterized FGL1/LAG-3, Siglec-15, MHC-I membrane inhibitors, and SARS-CoV-2 myeloid receptors, LAG-3/PD-1 dimer as potential mechanisms of immune regulation and targets for immunotherapy. He is the founder and scientific advisor for Remunix Inc., an advisor for BMS, Regeneron and Hanmi Pharmaceutical Ltd., an advisor and scientific co-founder for Rootpath Genomics, and a co-founder of BioSpark Group.